You can’t walk around Washington D.C. for long without meeting somebody who is involved in politics. The same is true for STEM jobs in the D.C. suburb of Gaithersburg, where one in every five employees in the city works in a STEM-related profession. The median salary for those employees is nearly $90,000, which is approximately $37,000 greater than the median income for the city overall.
University Startups are invited to apply to present at the next Global Corporate Venturing / Global University Venturing event in Houston, TX on November 8-9, 2018. Five startups will pitch to a room of approximately 50 corporate venture groups at this event. University Startups looking for their first investment or later rounds can apply. Startups presenting receive a one-day complimentary pass to attend the conference.
If you are a university with an active startup creation program, this is a must attend event to learn from international thought leaders about best practices in Global University Venturing. See below for the discount code to register.
Startups applying to the NCET2/GCV Showcase will also be considered for investments from the National Angels. The National Angels was specifically created by NCET2 to invest in the Best University Startups. The National Angels invests in companies in the following technical areas: Pharma/Med, Chemicals & Clean Tech, Advanced Manufacturing, and Information & Communication Technology. Investments range from $150,000 to $2 million.
HOW TO SUBMIT: Send your non-confidential pitch deck to submissions@ncet2.org. Submissions reviewed weekly. Final deadline for NCET2/GCV Houston Showcase is September 30, 2018.
For Dr. Carol Nacy, co-founder and CEO of Rockville, Maryland’s clinical-stage antibiotics developer Sequella, it all started with a fascination for things unseen.
Ben Young and Greg Coleman had their 15 minutes of fame when they shook hands with Mark Cuban on ABC’s “Shark Tank.” Then they had another moment in the spotlight, when that deal fell through.
Jeeva Informatics Solutions (Jeeva), a premier healthcare and life sciences informatics company with the vision to democratize precision medicine at community level, is participating this week in the inaugural Total Exposure Health 2018 conference at Bethesda, MD. The conference aims to bridge exposure health with precision medicine.
The Montgomery College Germantown Campus is celebrating its 40th Anniversary on Tuesday, October 16th at 12:30 PM in Globe Hall. The Germantown community day will be on March 30th from 12:00 PM – 4:00 PM.
MIT has been selected by the National Science Foundation (NSF) as an Innovation Corps (I-Corps) Node, and awarded $4.2 million in order to develop programs and resources that will accelerate the translation of fundamental research to practical applications.
Insect larvae-based feed additive/vaccine maker shifts focus to farmed shrimp These trays show R&D scale growth conditions for the insect larvae VakSea uses to produce its immune-boosting proteins.
Industrial IoT solutions innovator Machfu announced today that it is moving its corporate headquarters from the Germantown Innovation Center’s award- winning incubator program to commercial Class A office space in Rockville, Maryland. Machfu’s new headquarters will encompass 5,000 square feet of The Grove 270, a LEED Gold certified and Energy Star-awarded office complex.
Rare blood disorders are on VERALOX Therapeutics Inc.’s “hit” list. The company, a small molecule drug discovery and development firm based in the Frederick Innovative Technology Center, Inc. (FITCI), launched in September 2017 with a mission to develop a first-in-class therapeutic targeting rare immune-mediated blood disorders, beginning with heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT). These life-threatening diseases have a high mortality rate and often require limb amputations due to complications. The drug, VLX-1005, is the only therapeutic in development that strikes at the source of HITT and has performed impressively in clinically relevant animal models. Additionally, it has demonstrated preservation of insulin secretion and promotion of beta cell survival in newly-diagnosed type I diabetes patient samples, providing significant opportunities for market expansion into diabetes.
